Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian Drug Pricing Reforms Could Lead To Medicine Shortages

Executive Summary

Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.

You may also be interested in...



Canada Pulls Controversial Pricing Measures

Some measures aimed at reducing medicine prices in Canada have been dropped, to the relief of the pharmaceutical industry.

COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms

Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.

Pricing Reforms Prompt Canadian Business Rethink

The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.

Related Content

Topics

UsernamePublicRestriction

Register

PS140706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel